{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T19:41:42Z","timestamp":1784922102901,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2020R1F1A1074019"],"award-info":[{"award-number":["NRF-2020R1F1A1074019"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.bbrc.2021.12.065","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T10:10:42Z","timestamp":1639995042000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"588","author":[{"given":"Nami","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-E","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ja Young","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Jin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yup","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan Woo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.bbrc.2021.12.065_bib1","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/liv.14362","article-title":"Natural history of NASH and HCC","volume":"40","author":"Negro","year":"2020","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.bbrc.2021.12.065_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","article-title":"Pathogenesis of non-alcoholic fatty liver disease","volume":"103","author":"Dowman","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.bbrc.2021.12.065_bib3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cld.1045","article-title":"Nonalcoholic fatty liver disease and recent guideline updates","volume":"17","author":"Ando","year":"2021","journal-title":"Clinical Liver Disease"},{"issue":"2","key":"10.1016\/j.bbrc.2021.12.065_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bbrc.2021.12.065_bib5","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","article-title":"Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4)","volume":"23","author":"Thornberry","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metabol."},{"issue":"1","key":"10.1016\/j.bbrc.2021.12.065_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41598-020-57935-6","article-title":"Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects","volume":"10","author":"Kawakubo","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bbrc.2021.12.065_bib7","doi-asserted-by":"crossref","first-page":"E214","DOI":"10.1152\/ajpendo.00553.2014","article-title":"DPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-kappaB activation","volume":"309","author":"Shinjo","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.bbrc.2021.12.065_bib8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.bcp.2015.08.098","article-title":"A\u00a0dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression","volume":"98","author":"Hwang","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.bbrc.2021.12.065_bib9","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db10-1338","article-title":"Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice","volume":"60","author":"Shirakawa","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.bbrc.2021.12.065_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/met.2012.0128","article-title":"Effects of sitagliptin on nonalcoholic fatty liver disease in diet-induced obese rats","volume":"11","author":"Akaslan","year":"2013","journal-title":"Metab. Syndr. Relat. Disord."},{"issue":"2","key":"10.1016\/j.bbrc.2021.12.065_bib11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S2213-8587(13)70050-0","article-title":"SGLT inhibitors in management of diabetes","volume":"1","author":"Tahrani","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bbrc.2021.12.065_bib12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bbrc.2021.04.012","article-title":"Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: role of prostaglandin E2","volume":"557","author":"Yoshino","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2021.12.065_bib13","doi-asserted-by":"crossref","first-page":"106730","DOI":"10.1016\/j.intimp.2020.106730","article-title":"Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-alpha, IL-1beta, and IL-18 in rat liver","volume":"86","author":"ElMahdy","year":"2020","journal-title":"Int. Immunopharm."},{"issue":"18","key":"10.1016\/j.bbrc.2021.12.065_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.21037\/atm.2019.09.03","article-title":"The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus","volume":"7","author":"Leng","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.bbrc.2021.12.065_bib15","first-page":"9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-kappaB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","author":"Lee","year":"2021","journal-title":"J\u00a0Immunol Res 2021"},{"key":"10.1016\/j.bbrc.2021.12.065_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2014.10.008","article-title":"Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in\u00a0vitro and in\u00a0vivo","volume":"744","author":"Jung","year":"2014","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbrc.2021.12.065_bib17","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.metabol.2015.10.010","article-title":"The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db\/db mice both as monotherapy and in combination with linagliptin","volume":"65","author":"Kern","year":"2016","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.bbrc.2021.12.065_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A\u00a0simple method for the isolation and purification of total lipides from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J.\u00a0Biol. Chem."},{"issue":"6","key":"10.1016\/j.bbrc.2021.12.065_bib19","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/j.1440-1746.2009.06196.x","article-title":"Oxidative stress and regulation of anti-oxidant enzymes in cytochrome P4502E1 transgenic mouse model of non-alcoholic fatty liver","volume":"25","author":"Kathirvel","year":"2010","journal-title":"J.\u00a0Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.bbrc.2021.12.065_bib20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5009\/gnl.2012.6.2.149","article-title":"NASH is an inflammatory disorder: pathogenic, prognostic and therapeutic implications","volume":"6","author":"Farrell","year":"2012","journal-title":"Gut Liver"},{"issue":"1","key":"10.1016\/j.bbrc.2021.12.065_bib21","doi-asserted-by":"crossref","first-page":"7499","DOI":"10.1038\/s41598-018-25699-9","article-title":"Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis","volume":"8","author":"Kim","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2021.12.065_bib22","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.3389\/fimmu.2020.01802","article-title":"Chemokines in non-alcoholic fatty liver disease: a systematic review and Network meta-analysis","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2021.12.065_bib23","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1017\/erm.2016.16","article-title":"C-X-C motif chemokine 10 in non-alcoholic steatohepatitis: role as a pro-inflammatory factor and clinical implication","volume":"18","author":"Xu","year":"2016","journal-title":"Expet Rev. Mol. Med."},{"key":"10.1016\/j.bbrc.2021.12.065_bib24","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.freeradbiomed.2017.09.016","article-title":"Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4\/NOX1-mediated regulation of superoxide","volume":"113","author":"Long","year":"2017","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2021.12.065_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41598-020-80689-0","article-title":"LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH","volume":"11","author":"Takata","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2021.12.065_bib26","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S1734-1140(09)70133-1","article-title":"Inhibitors of type 2 sodium glucose co-transporters \u2013 a new strategy for diabetes treatment","volume":"61","author":"Bo\u0142dys","year":"2009","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbrc.2021.12.065_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"44","key":"10.1016\/j.bbrc.2021.12.065_bib28","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.3748\/wjg.v22.i44.9706","article-title":"Galectin-3 and IL-33\/ST2 axis roles and interplay in diet-induced steatohepatitis","volume":"22","author":"Pejnovic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.bbrc.2021.12.065_bib29","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21017009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X21017009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:13:57Z","timestamp":1757765637000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X21017009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":29,"alternative-id":["S0006291X21017009"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.12.065","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2021.12.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}